ALT Altimmune, Inc.
USHealthcareAs of 2026-07-10 13:26
Why ALT matters now
Altimmune, Inc. (ALT) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.05 with -2.25% on the session and $269.2M in market capitalization; recent performance reads 1-month -1.46% and YTD -25.21%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-22.6M, and EPS of $-0.18. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -30.2%.
The latest indexable market news headline is "Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $11.25; recent insider activity includes SAYARE MITCHEL filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.18
P/S
6619.30
EV/EBITDA
-2.00
DCF Value
$0.08
FCF Yield
-30.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-41519.4%
Operating Margin
-269216.7%
Net Margin
-253002.8%
ROE
-42.6%
ROA
-27.1%
ROIC
-29.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-22.6M | $-0.18 |
| Q4 2025 | $26.0K | $-27.4M | $-0.27 |
| FY 2025 | $41.0K | $-88.1M | $-1.00 |
| Q3 2025 | $5.0K | $-19.0M | $-0.21 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$11.25
Target (Median)
$11.25
Target Range
$2.50 - $20.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.23
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.